Chemical Modification of Paclitaxel (Taxol) Reduces P-Glycoprotein Interactions and Increases Permeation across the Blood−Brain Barrier in Vitro and in Situ-Reference-Cited by-同舟云学术

Chemical Modification of Paclitaxel (Taxol) Reduces P-Glycoprotein Interactions and Increases Permeation across the Blood−Brain Barrier in Vitro and in Situ

Published:2005-01-05 Issue:3 Volume:48 Page:832-838
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Rice Antonie¹,Liu Yanbin¹,Michaelis Mary Lou¹,Himes Richard H.¹,Georg Gunda I.¹,Audus Kenneth L.¹

Affiliation:

1. Department of Pharmaceutical Chemistry, University of Kansas, 226 Simons, 2095 Constant Avenue, Lawrence, Kansas 66047, Department of Pharmacology and Toxicology, University of Kansas, Malott Hall 5064, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, Department of Medicinal Chemistry, University of Kansas, Malott Hall 4070, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, and Department of Molecular Biosciences, University of Kansas, Haworth Hall 2034, 1200 Sunnyside Avenue, Lawrence, Kansas 66045

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm040114b

Reference30 articles.

1. Taxol Science and Applications; Suffness, M., Ed.; CRC: Boca Raton, FL, 1995.

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

2. Recent Uses of Lipid Nanoparticles, Cell-Penetrating and Bioactive Peptides for the Development of Brain-Targeted Nanomedicines against Neurodegenerative Disorders;Nanomaterials;2023-11-23

3. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours;Nature Reviews Clinical Oncology;2023-04-21

4. NorA, Tet(K), MepA, and MsrA Efflux Pumps in Staphylococcus aureus, their Inhibitors and 1,8-Naphthyridine Sulfonamides;Current Pharmaceutical Design;2023-02

5. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery;Pharmaceutics;2022-12-24